Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Blood

Volumn 122, Issue 8, 2013, Pages 1384-1394

  Burnett, Alan K ^a   Russell, Nigel H ^b   Hunter, Ann E ^c   Milligan, Donald ^d   Knapper, Steven ^e   Wheatley, Keith ^f   Yin, John ^g   McMullin, Mary F ^h   Ali, Sahra ⁱ   Bowen, David ^j   Hills, Robert K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h BELFAST CITY HOSPITAL   (United Kingdom)

ⁱ CASTLE HILL HOSPITAL   (United Kingdom)

^j LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; DIARRHEA; DISEASE DURATION; FEMALE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SECONDARY ACUTE MYELOID LEUKEMIA; SIDE EFFECT; TREATMENT RESPONSE; VERY ELDERLY; ACUTE GRANULOCYTIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; MORTALITY; PROPORTIONAL HAZARDS MODEL; REMISSION; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84886859143     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-496596     Document Type: Article

References (19)

1. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597-1603.
2. Juliusson G, Billström R, Gruber A, et al; Swedish Adult Acute Leukemia Registry Group. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia. 2006;20(1):42-47.
3. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187.
4. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-279.
5. Burnett AK, Milligan D, Goldstone A, et al; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318-332.
6. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-1124.
7. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
8. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
9. Hills RK, Burnett AK. Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood. 2011;118(9):2389-2394.
10. Lindemalm S, Liliemark J, Juliusson G, Larsson R, Albertioni F. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett. 2004;210(2):171-177.
11. Avramis VI, Plunkett W. 2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine. Biochem Biophys Res Commun. 1983;113(1):35-43.
12. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA III. Synthesis and biologic activity of 29-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem. 1992;35(2):397-401.
13. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102(7): 2379-2386.
14. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4):549-555.
15. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010;28(14):2389-2395.
16. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606-4613.
17. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for diagnosis Standardisation, of Response Criteria Treatment Outcomes and Reporting Standards for Therapeutic Trials In Acute Myeloid Leukaemia. J Clin Oncol. 2003; 21(24):4642-4649.
18. Wheatley K, Brookes CL, Howman AJ, et al; United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598-605.
19. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 2013;27(1):75-81.